开发基于乙基化的CGRP受体抗剂的管道,其半衰期为偏头痛治疗延长
Jens Bjelke Kristensen1,2, Lisbeth Elster3, Morten Lundh3
1Gubra ApS, Hørsholm Kongevej 11B, DK-2970, Hørsholm, Denmark. jbj@gubra.dk.
Scientific reports
|January 13, 2025
概括
研究人员开发了一种类药物来治疗偏头痛,该药物向阿尔法素基因相关 (αCGRP). 脂化改善了该药物的半衰期和效力,显示出新的偏头痛治疗的前景.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 偏头痛是一种常见的神经疾病,具有神经血管起源.
- 阿尔法素基因相关 (αCGRP) 在偏头痛病理生理学中起着关键作用,引发血管扩张效应.
- 针对CGRP信号已经成为一项有效的偏头痛治疗策略.
研究的目的:
- 为人类CGRP (hCGRP) 受体开发一种基于的抗体,其半衰期延长.
- 研究脂化对hCGRP受体对抗剂的药理动力学特性和功效的影响.
- 为了确定增强基于的hCGRP抗剂疗效的特定修改.
主要方法:
- 合成和查hCGRP8-37类似物与不同的脂化 (C18-二酸与C20-二酸).
- 在实验室中对受体对抗性和在小鼠体内药理动力学研究的评估.
- 氨基酸替代扫描以优化对抗剂的功效和疗效.
主要成果:
- 与C20-二酸性脂化相比,hCGRP8-37类似物表现出比C18-二酸性类似物强度的2-6倍.
- 在小鼠中C20-二酸相似物估计的半衰期在7.3小时至13.7小时之间.
- 在位置25的C20-亚酸和位置36的氨酸-氨酸替代物的特定类比显示出强度增加了约4倍,并成功对抗hCGRP诱导的血管扩张.
结论:
- 脂化hCGRP8-37类似物显著增强药物动力学特性,包括半衰期.
- 战略性氨基酸修改可以进一步提高基于的CGRP抗剂的效力.
- 这些发现支持脂化改性抗剂的发展,作为对偏头痛治疗的可行的治疗策略.
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
147
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
147
Ligand-Gated Ion Channel Receptor: Gating Mechanism
2.1K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
2.1K


